secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001213900-25-041063
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq Panel finds CERo Therapeutics again compliant with $2.5M equity rule
---------------------------------------------------------------------------

- On May 7, 2025, Nasdaq Hearings Panel determined CERo complied with Listing Rule 5550(b)(1) (minimum $2.5M stockholders' equity).
- Compliance achieved through Series D Preferred private placement (4/21/2025), Equity Line drawdown, and public offering in Feb 2025.
- CEO Chris Ehrlich says company now focused on lead program CER-1236; anticipates first patient dose in Phase 1 trial soon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025041063/0001213900-25-041063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025041063/ea0241411-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-041063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer